Clinical study of Gushen tablet in reducing children’s nephrotic syndrome relapse

Yun Ying; Gao Ya; Ma Yu-hong; Liu Wang-le; Zhao Meng; Gao Zhi-ming

doi:10.1007/BF02838029

Your Location：

Home >

Browse articles >

Clinical study of Gushen tablet in reducing children’s nephrotic syndrome relapse

OriginalPaper | Updated：2021-08-27

- Clinical study of Gushen tablet in reducing children’s nephrotic syndrome relapse
- Clinical study of Gushen tablet in reducing children’s nephrotic syndrome relapse
- 中国结合医学杂志（英文版） 2003年9卷第3期页码：185-190
- Affiliations：
  
  1. The First Affiliated Hospital, Henan College of TCM,Zhengzhou
  2. Henan Academy of TCM,China
  3. Hospital of Henan TCM College,China
  4. Zhengzhou City Children Hospital,China
- Author bio：
- Funds：
  
  The item was supported by the Science and Technology Department of Henan Province (No. 941200528)
- DOI：10.1007/BF02838029
  中图分类号：
- 纸质出版日期：2003，
Scan for full text
Ying, Y., Ya, G., Yu-hong, M. et al. Clinical study of Gushen tablet in reducing children’s nephrotic syndrome relapse., Chin. J. Integr. Med. 9, 185–190 (2003). https://doi.org/10.1007/BF02838029

Yun Ying, Gao Ya, Ma Yu-hong, et al. Clinical study of Gushen tablet in reducing children’s nephrotic syndrome relapse[J]. Chinese Journal of Integrative Medicine, 2003,9(3):185-190.
Ying, Y., Ya, G., Yu-hong, M. et al. Clinical study of Gushen tablet in reducing children’s nephrotic syndrome relapse., Chin. J. Integr. Med. 9, 185–190 (2003). https://doi.org/10.1007/BF02838029 DOI：

Yun Ying, Gao Ya, Ma Yu-hong, et al. Clinical study of Gushen tablet in reducing children’s nephrotic syndrome relapse[J]. Chinese Journal of Integrative Medicine, 2003,9(3):185-190. DOI： 10.1007/BF02838029.

摘要

Objective: To explore the effect of Gushen tablet (GST) in reducing the relapse of children’s nephrotic syndrome and the possible mechanism of drugs used.Methods: Fifty children with primary nephrotic syndrome who had been induced and alleviated with regular glucocorticoid (GC) were randomly divided into two groups: the GST group used GST and standard middle-long term course of GC

and the control group adopted standard middle-long term course of GC and immunoinhibitory or immunomodulatory agents for treatment. The 0. 5

1 and 2 years after the treatment the relapse episodes

time for urinary protein negative conversion after relapse

the episodes of patients infection and relapse after infection were evaluated. Before and after treatment the plasma cortisol and T lymphocyte subpopulation were determined.Results: The relapse rate of GST group: the rates after 0. 5

2 years were 20. 0%

30. 0% and 40. 9%

and the frequent relapse rate were 0

6. 7% and 9. 2% respectively

which were lower than those of control group (60. 0%

70. 0%

69. 2% and 25. 0%

15. 0%

15. 4% respectively); in the GST group no relapse occurred within 0. 5 year

the relapse rate after 1 and 2 years reduced by 40. 0% and 28. 3%

compared with those of the control group (allP < 0.05); during the observation period

the mean infection/every child patient was 1. 86 episodes in GST group

after infection the nephrotic relapse rate was 28. 3%

which was lower than that of the control group (2. 25 episodes

71.1%

P < 0.05); the relapse per patient in GST group was 0. 8 episodes

time for urinary protein negative conversion was 12. 00± 8. 98 days

lower than those of control group (1. 6 episodes

20. 75±11. 95 days

P < 0. 05); 3 months after GST treatment the plasma cortisol level normalized

and the CD4/CD8 ratio elevated (P < 0.05).Conclusion: GST could possibly reduce the relapse of children nephrosis

and the frequent relapse and relapse episodes

and the time for post-relaptic urinary protein negative conversion shortened

the plasma cortisol elevated

and the adjustment of cellular immunity disturbance promoted.

Abstract

and the control group adopted standard middle-long term course of GC and immunoinhibitory or immunomodulatory agents for treatment. The 0. 5

1 and 2 years after the treatment the relapse episodes

time for urinary protein negative conversion after relapse

2 years were 20. 0%

30. 0% and 40. 9%

and the frequent relapse rate were 0

6. 7% and 9. 2% respectively

which were lower than those of control group (60. 0%

70. 0%

69. 2% and 25. 0%

15. 0%

15. 4% respectively); in the GST group no relapse occurred within 0. 5 year

the relapse rate after 1 and 2 years reduced by 40. 0% and 28. 3%

compared with those of the control group (allP < 0.05); during the observation period

the mean infection/every child patient was 1. 86 episodes in GST group

after infection the nephrotic relapse rate was 28. 3%

which was lower than that of the control group (2. 25 episodes

71.1%

P < 0.05); the relapse per patient in GST group was 0. 8 episodes

time for urinary protein negative conversion was 12. 00± 8. 98 days

lower than those of control group (1. 6 episodes

20. 75±11. 95 days

P < 0. 05); 3 months after GST treatment the plasma cortisol level normalized

and the CD4/CD8 ratio elevated (P < 0.05).Conclusion: GST could possibly reduce the relapse of children nephrosis

and the frequent relapse and relapse episodes

and the time for post-relaptic urinary protein negative conversion shortened

the plasma cortisol elevated

and the adjustment of cellular immunity disturbance promoted.

关键词

Gushen tabletchildren nephrotic syndromerelapseadrenocortical functionT lymphocyte subpopulation

Keywords

Gushen tabletchildren nephrotic syndromerelapseadrenocortical functionT lymphocyte subpopulation

references

WANG BL. Children nephrology. 1st edition. Beijing: People’s Health Publishing House, 1983: 165.

JIANG XY, CHEN RH, WANG BL. On suggestions of clinical classification and treatment of glomeruli diseases. Chin J Pediatr 1981;19(4): 241–242.

Ministry of Health PRC worked out and promulgated. Guiding principle of Chinese new drugs in clinical study of nephrotic syndrome. Guiding Principle of Chinese New Grugs in Clinical Study 1993; 1: 158–161.

WU L, GUO YQ, GUO MY, et al. Pathologic observation and clinical analysis of frequent relapse of nephrotic syndrome. Chin J Pediatr 1995;33(4): 237–238.

WU L, GUO YQ, GUO MY, et al. Follow-up observation of 47 cases of frequent relapse of nephrotic syndrome and analysis. Chin J Pract Pediatr 1996; 11 (3): 151–152.

GAO JL, WANG YQ. Clinical significance of adrenal cortical function monitoring on children hormone sensitive type of nephrosis syndrome. Chin Med J 1990; 70 (5): 273.

LIU AM. Cause of 59 cases of children nephrosis syndrome relapse. J Pract Pediatr 1995; 10(6): 341.

LIU JC, WANG BL, CHEN H. Therapeutic effect of corticosteroid middle long term treatment in treating primary nephrosis syndrome and its early stage prediction. Chin J Pediatr 1987; 25(2): 77–79.

NIU JZ, ZHANG Y, WANG ZG, et al. Study on antagonizing effect of Gynostemma glycosides on dexamethasone induced adrenal cortical change in mice. Chin J TCM Pharm 1990; 5(5): 17–19.

ZOU HQ, WANG YQ, KUANG YF. Exploration on mutual relationship of glucocortico-steroid in regulating circuit and simple nephrotic syndrome. Chin J Pediatr 1993; 31(5): 276.

ZHAO JL, XU XH, WANG BL, et al. Relationship between infantile simple nephrosis syndrome and adrenal cortical syndrome. Chin J Pediatr 1988; 26(4): 230–232.

WU L, XU SX, GUO YQ, et al. Controlled observation of adrenal cortical functional determination for frequently occurred nephrosis syndrome. Clin J Pediatr 1997; 15: (5)280–281.

JIANG CH, ZHONG XL, GU TJ, et al. Research on Shen. 2nd edition. Shanghai: Shanghai Science and Technology Press, 1983; 10: 122–123.

LIU YF, KANG JN, PENG YF, et al. Effect of gynostemma in treating deficiency syndrome and its effect on plasma cortisol. Pract J TCM 1993; 9(1): 21–23.

SHEN ZY. Orientated study of Shen yang deficiency. Chin J Integr Tradit West Med 1997; 17(1): 50–51.

WANG YQ, ZOU HQ, GAO JL, et al. Exploration on using astragalus and acanthopanax to reduce relapse of children primary nephrotic syndrome. Chin J Pediatr 1992; 30(3): 137–138.

FULL TEXT LINK

More>

浏览量

398

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Effects of tripterygii totorum in treating insulin dependent diabetes mellitus patients with islet transplantation